Lv5133
1310 积分 2023-10-10 加入
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1天前
已完结
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non small-cell lung cancer
1天前
已完结
Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment
1天前
已完结
Incidence of venous thromboembolism in patients with cancer – A cohort study using linked United Kingdom databases
9天前
已完结
Benmelstobart Ups ES-SCLC Survival
3个月前
已完结
Sunitinib in the Treatment of Thyroid Cancer
4个月前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
4个月前
已完结
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
